CPA
JBIO icon

Capital Performance Advisors’s Jade Biosciences JBIO Stock Holding History

Capital Performance Advisors’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2
Closed -$167 – 410
2024
Q3 		$167 Buy
+2
New +$129 ﹤0.01% 2598

Other funds holding JBIO

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Logos Global Management
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
AI
Allostery Investments Stamford, Connecticut $7.85M AUM

Capital Performance Advisors's JBIO Position: Q4 2024 in Review

Capital Performance Advisors sold out of Jade Biosciences (JBIO) in Q4 2024, closing a stake of 2 shares — an estimated $167 sold.

Capital Performance Advisors first reported a position in JBIO in Q3 2024 and held it in 1 quarter. The position peaked at $167 in Q3 2024. 78 funds tracked by Wall St. Rank hold JBIO as of Q4 2024.

  • Capital Performance Advisors reported no remaining Jade Biosciences position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 2 Jade Biosciences shares in Q4 2024, an estimated $167.
  • Capital Performance Advisors first reported a position in Jade Biosciences in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Jade Biosciences position peaked at $167 in Q3 2024.
  • 78 funds tracked by Wall St. Rank held Jade Biosciences as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.